Answers are grounded in this paper and cite their sources.
Observational study shows strong COX2 expression associates with advanced stage and reduced survival in esophageal squamous cell carcinoma, highlighting its potential prognostic utility.
Topic Esophageal Cancer: Molecular Biology/Pathology Background The focus of studies on cyclooxygenase-2 (COX2) have been on its ability to mediate the biological behavior of human tumors including tumorigenesis, tumor progression, apoptosis and differentiation. The aim of the current study was to elucidate a further finding on the clinicopathologic significance of immunohistochemical expression of COX2 in esophageal squamous cell carcinoma. Methods The immunohistochemical expression of COX2 was examined for 68 specimens of esophageal squamous cell carcinoma (ESCC) and the correlation of COX2 expression with clinicopathologic features was examined. COX2 immunoreactivity was weak in 27 (40%) and strong in 41 (60%) of the carcinomas. Results The proportion of poorly differentiated SCCs among tumors with a strong expression of COX2 (34%, 14 of 41) was significantly higher than among tumors with a weak expression of COX2 (19%, 3 of 14, p = 0.02). The depth of the tumors (p = 0.0004), lymph node metastasis (p = 0.009) and the stage of the tumors (p = 0.001) were advanced significantly more progressively in ESCCs with a strong COX2 expression. Moreover, survival was significantly reduced (p = 0.02) among patients with strong COX2 expression when compared with the COX2 weak group. Conclusion This study showed that strong expression of COX2 was correlated with tumor progression and poor differentiation in ESCC.
No takes yet. Share an insight, caveat, or question.
Naoki Hashimoto (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: